Recent

% | $
Quotes you view appear here for quick access.

The Blackstone Group L.P. Message Board

curley5 6 posts  |  Last Activity: Jul 29, 2015 10:51 AM Member since: Feb 26, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    I bought all I could today.

    by buda8901 Jul 29, 2015 10:05 AM
    curley5 curley5 Jul 29, 2015 10:51 AM Flag

    Gilead Worth $125 After Earnings: Morgan Stanley

  • Reply to

    Who will be first to put out an UPGRADE

    by jd39souza98 Jul 29, 2015 7:12 AM
    curley5 curley5 Jul 29, 2015 8:06 AM Flag

    Gilead Sciences GILD RBC Capital Mkts Outperform $120 » $130
    Gilead Sciences GILD Maxim Group Buy $127 » $129
    Gilead Sciences GILD Needham Buy $120 » $125

  • EXASFollow
    EXACT Sciences Corporation Short Interest
    $31.16* 0.160.52%
    *Delayed - data as of Jun. 24, 2015 - Find a broker to begin trading EXAS now Exchange: NASDAQ
    Industry: Health Care
    Community Rating: Bullish
    EXAS

    Edit Symbol List
    Symbol Lookup
    SYMBOL LIST VIEWS

    FlashQuotes
    InfoQuotes
    STOCK DETAILS

    Summary Quote
    Real-Time Quote
    After Hours Quote
    Pre-market Quote
    Historical Quote
    Option Chain
    CHARTS

    Basic Chart
    Interactive Chart
    COMPANY NEWS

    Company Headlines
    Press Releases
    Market Stream
    STOCK ANALYSIS

    Analyst Research
    Guru Analysis
    Stock Report
    Competitors
    Stock Consultant
    Stock Comparison
    FUNDAMENTALS

    Call Transcripts
    Annual Report
    Income Statement
    Revenue/EPS
    SEC Filings
    Short Interest
    Dividend History
    HOLDINGS

    Ownership Summary
    Institutional Holdings
    Insiders
    (SEC Form 4)
    Save Stocks
    Settlement Date Short Interest Avg Daily Share Volume Days To Cover
    6/15/2015 29,144,213 1,138,168 25.606249

    Read more: http://www.nasdaq.com/symbol/exas/short-interest#ixzz3e2D9O7YR

  • Reply to

    Great another upgrade $33

    by curley5 Jun 24, 2015 2:33 PM
    curley5 curley5 Jun 24, 2015 9:43 PM Flag

    EXACT Sciences’ DeeP-C study meets the majority of USPSTF criteria for "high-quality evidence"
    Cologuard's superior analytical performance positions it favorably relative to other A/B-rated screening options
    USPSTF's focus on benefits vs. harms favors Cologuard's non-invasive approach relative to colonoscopy
    Latest Ratings for EXAS
    Date Firm Action From To
    May 2015 JMP Securities Maintains Market Outperform

  • In a report published Friday, Jefferies analyst Brandon Couillard maintained a Buy rating on EXACT Sciences Corporation (NASDAQ: EXASOpens Flyout Module that includes Quote information for linked symbol), with a price target of $33.

    The US Preventive Services Task Force (USPSTF) is scheduled to publish its revised guidelines for CRC screening in the coming months, including an assessment of Cologuard.

  • curley5 by curley5 Jun 19, 2015 3:28 PM Flag

    n a report published Friday, Jefferies analyst Brandon Couillard maintained a Buy rating on EXACT Sciences Corporation (NASDAQ: EXASOpens Flyout Module that includes Quote information for linked symbol), with a price target of $33.

    The US Preventive Services Task Force (USPSTF) is scheduled to publish its revised guidelines for CRC screening in the coming months, including an assessment of Cologuard.

    “Under the ACA, all services with an A or B rating by USPSTF are required to be fully-covered by commercial insurers at no cost to patients. An A/B rating would also secure Cologuard a slot in HEDIS quality measures, a key financial incentive for adoption by large systems/networks,” analyst Brandon Couillard said.

BX
33.67+0.19(+0.57%)Sep 4 4:02 PMEDT